After finishing at $26.28 in the prior trading day, Dyne Therapeutics Inc (NASDAQ: DYN) closed at $27.52, up 4.72%. In other words, the price has increased by $+1.24 from its previous closing price. On the day, 714909 shares were traded.
Ratios:
Our goal is to gain a better understanding of DYN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 2.53. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 20, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On February 27, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform and also upped its target price recommendation from $16 to $27.
On February 15, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $34.Oppenheimer initiated its Outperform rating on February 15, 2023, with a $34 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 12 ’24 when Farwell Wildon sold 1,030 shares for $25.58 per share. The transaction valued at 26,347 led to the insider holds 150,560 shares of the business.
Brumm Joshua T sold 66,387 shares of DYN for $1,704,142 on Mar 11 ’24. The CEO & President now owns 537,998 shares after completing the transaction at $25.67 per share. On Mar 11 ’24, another insider, McNeill Jonathan, who serves as the Chief Business Officer of the company, sold 19,601 shares for $25.50 each. As a result, the insider received 499,842 and left with 139,408 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 2.16B and an Enterprise Value of 2.06B.
Stock Price History:
The Beta on a monthly basis for DYN is 0.95, which has changed by 139.72% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $30.27, while it has fallen to a 52-week low of $6.40. The 50-Day Moving Average of the stock is 22.39, while the 200-Day Moving Average is calculated to be 13.60.
Shares Statistics:
The stock has traded on average 2.19M shares per day over the past 3-months and 2.13M shares per day over the last 10 days, according to various share statistics. A total of 61.47M shares are outstanding, with a floating share count of 49.93M. Insiders hold about 38.44% of the company’s shares, while institutions hold 52.77% stake in the company. Shares short for DYN as of Feb 29, 2024 were 6.61M with a Short Ratio of 3.01, compared to 8.55M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.06% and a Short% of Float of 10.06%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.8 for the current quarter, with a high estimate of -$0.75 and a low estimate of -$0.83, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.8, with high estimates of -$0.7 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.82 and -$3.6 for the fiscal current year, implying an average EPS of -$3.27. EPS for the following year is -$3.17, with 5 analysts recommending between -$2.19 and -$4.48.
